How to Buy Abbvie Stock
Abbvie Inc
Abbvie is a general drug manufacturer company located in Illinois, United States, which is part of the Healthcare sector, and is traded under the ticker ABBV on the NYSE exchange.
Abbvie stock last closed at $220.81, up 2.1% from the previous day, and has increased 14.14% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.25 percentage points. Abbvie stock is currently +34.8% from its 52-week low of $163.81, and -0.43% from its 52-week high of $221.77.
As of Sep 17, 2025, there are 1.77B shares of ABBV outstanding. The market value of ABBV is $390.07B. In the last 24 hours, 5.26M ABBV shares were traded.
How to Buy Abbvie Stock
Not sure how to invest in Abbvie stock? Here's how.
- Figure out where to buy Abbvie stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you figure out where to buy Abbvie stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Select your method of payment and add your details.
- Evaluate Abbvie stock: The Abbvie ticker symbol is ABBV. Is Abbvie stock a good investment? Should you buy shares of ABBV? How do ABBV's underlying business fundamentals look? Do top analysts think Abbvie is a good buy? Why has ABBV's stock price moved recently? (Hint: Our stock research website can help you decide if ABBV is a good stock to buy).
- Execute your ABBV purchase: Decide if you will purchase ABBV shares at the current market price or use a limit order to buy ABBV stock at a given price.
- Keep tabs on your investment in ABBV: Create a watchlist to watch your investment in Abbvie stock.
Step 1: Figure out where to buy Abbvie stock
You need a brokerage account in order to access the NYSE market and buy ABBV shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Tech to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've selected your brokerage, it's time to fill out some personal details so you are able to invest in ABBV stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to start a new brokerage account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have opened your account on a good stock buying app, you need to deposit funds:
Check out the walkthrough below if you need help depositing money into your brokerage account.
Step 4: Evaluate Abbvie stock
After you have figured out the best place to buy Abbvie stock, it's important to research their stock before you buy, so you can comprehend the risk as well as the opportunity.
Abbvie Numbers
Abbvie Overview
WallStreetZen was created to help part-time investors perform better fundamental analysis quickly.
You can view all of the due diligence checks on ABBV's stock page.
How is ABBV stock valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge ABBV's true value.
Using relative valuations metrics:
- ABBV could be overvalued based on its P/E ratio of 104.65x, relative to Drug Manufacturers - General industry P/E ratio of 37.55x
- ABBV may be overvalued based on its PEG ratio of 1.08x
You can access additional valuation analysis on ABBV's stock here.
A quick look at ABBV Financials
Passed Health Checks:
- ABBV's operating cash flow of $19.28B allows it to safely service it's debt of $70.48B.
Failed Health Checks:
- There are more long-term liabilities than short-term assets on the ABBV balance sheet.
- ABBV profit margin has gone down from 9.7% to 6.5% in the past year.
- There are more short-term liabilities than short-term assets on the ABBV balance sheet.
- ABBV earnings of $5.53B is not enough to cover its interest payments.
- Total ABBV debt is still negative.
- ABBV debt to equity ratio of -750.38 is negative.
Is ABBV stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 13 sell side analysts who give ratings on ABBV, the consensus analyst rating on Abbvie is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Most Recent ABBV Analyst Upgrades/Downgrades
David Amsellem, a top 7% analyst from Piper Sandler assumes ABBV with a strong buy rating and announces their ABBV price target of $231.00, on Aug 12, 2025.
Gavin Clark-Gartner, a bottom 5% analyst from Evercore ISI Group maintains ABBV with a buy rating and raises their ABBV price target from $205.00 to $207.00, on Aug 1, 2025.
Vamil Divan, a top 4% analyst from Guggenheim maintains ABBV with a strong buy rating and raises their ABBV price target from $216.00 to $227.00, on Aug 1, 2025.
Guggenheim's Vamil Divan raised their price target on Abbvie (NYSE: ABBV) by 5.1% from $216 to $227 on 2025/08/01. The analyst maintained their Strong Buy rating on the stock.
AbbVie reported its Q2 2025 earnings.
Divan told readers that after "another strong quarter," management raised full-year revenue and EPS guidance for the second time this year.
In response, the analyst said they updated their AbbVie model to account for "higher Skyrizi and neuroscience estimates, a steeper Humira erosion curve, and slightly lower aesthetics estimates."
Earnings Report
For Q2 2025, AbbVie reported:
- EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89 and Q2 2024's $2.65.
- Revenue of $15.42B, which beat the Zacks Consensus Estimate by 2.35% and Q2 2024's $14.46B.
For FY 2025, management guided:
- EPS of $11.88 to $12.08, up from the prior 11.67 to $11.87.
Chairman & CEO Robert A. Michael commented: "AbbVie delivered another outstanding quarter with strong performance from our diversified growth platform.
"We also made meaningful pipeline progress with several regulatory approvals, encouraging clinical data and strategic investments in promising external innovation.
"We're entering the second half of the year with substantial momentum and are once again raising our full-year outlook."
Terence Flynn, a top 11% analyst from Morgan Stanley maintains ABBV with a strong buy rating and raises their ABBV price target from $250.00 to $255.00, on Aug 1, 2025.
Gary Nachman, a top 29% analyst from Raymond James maintains ABBV with a buy rating and raises their ABBV price target from $227.00 to $236.00, on Aug 1, 2025.
You can dive deeper into what analysts are forecasting on the Abbvie stock forecast page.
ABBV Technicals
ABBV Performance Numbers
Last year, ABBV earnings were $3.76B. Over the last 5 year, ABBV's earnings have grown by -14.87% per year. This was slower than the Drug Manufacturers - General industry average of 6.04%.
Last year, ABBV revenue was $58.33B. Over the past five year, ABBV's revenue has grown by 9.99% per year. This was faster than the Drug Manufacturers - General industry average of 9.94%.
Dig into ABBV's earnings and revenue performance here.
Are ABBV executives and large shareholders buying or selling the stock?
Over the last 12 months, executives and large shareholders at ABBV have sold more shares than they have bought.
Azita Salekigerhardt, EVP CHIEF OPERATIONS OFFICER of ABBV, was the latest ABBV insider to buy. They bought $2,324,418.20 worth of ABBV stock on Aug 12, 2025.
Learn more about who owns ABBV shares here.
Does ABBV stock generate passive income?
Abbvie pays a dividend of 2.19%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.03%. If you owned $1,000 worth of ABBV stock, you would have received $21.87 in the past 12 months.
Abbvie dividend payments have consistently grown over the past decade and have remained stable.
Get more info about Abbvie dividend yield and history here.
ABBV Social Trading Data
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your ABBV purchase
There are two main options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually the easiest way to buy. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a given price limit, place a limit order.
Press the Open Trade button and your broker will place the order.
If you require additional assistance investing in stocks on eToro, click the how to video below:
Step 6: Keep tabs on your investment in ABBV
Now that you own some shares in ABBV, you'll want to keep up with your investment.
Put ABBV on a watchlist to see the latest developments about your ABBV stock.
ABBV Feed
How to Buy Stock in Abbvie
To reiterate, here are the 6 steps to buy stock in Abbvie:
- Figure out where to buy Abbvie stock
- Sign up for a brokerage account
- Deposit funds into your brokerage account
- Evaluate Abbvie stock
- Execute your ABBV purchase
- Keep tabs on your investment in ABBV
If you require a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you want to monitor your investment in Abbvie, create a watchlist today.
More "How To" Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.